News
Vektor Medical Presents AI-Powered Research at HRX 2024
Vektor's Chief Technology Officer, Chris Villongco, will present two studies at HRX 2024, showcasing the innovative use of AI in analyzing wall thickness and scar tissue in ventricular tachycardia patients. These studies, selected for the Top 5 AbstracX session, demonstrate Vektor’s cutting-edge approach to improving VT treatment.
The first study highlights the integration of vMap’s AI-driven ECG analysis with CT data for precise localization of VT sources, optimizing ablation procedures. The second study validates the accuracy of Vektor’s AI models in analyzing myocardial wall thickness, further enhancing VT care.
Vektor Medical Rhythm Theater at HRS '24
Friday, May 17th from 4–5pm, Rhythm Theater 2
The Future of Care: Leveraging AI for ArrhythmiaLocalization
Join us for an in-depth discussion on the future of AI-driven ablation and discover how vMap seamlessly integrates into existing workflows, elevating patient care and driving more efficient procedures.
Visit Vektor's Booth #669 for a demo.
vMap Study Results Published In The Journal of Cardiovascular Electrophysiology
A recent publication in the Journal of Cardiovascular Electrophysiology (JACE) highlights the efficacy of vMap in optimizing the treatment process for patients with cardiac arrhythmias undergoing ablation therapy.
The “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types. Designed to evaluate the impact of AI ECG mapping on time to ablation, procedural duration, and fluoroscopy, key data points from the study demonstrate vMap’s ability to deliver:
- 19.0% reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p = 0.02)
- 22.6% reduction in procedure duration (233 ± 51 vs. 301 ± 83 min, p < 0.001)
- 43.7% reduction in fluoroscopy (18.7 ± 13.3 vs. 33.2 ± 18.0 min, p < 0.001)
Additionally, at six-month follow-up, arrhythmia-free survival was evident in 73.5% of the study group compared to 63.3% of the control group (p = 0.56).
Vektor Medical Wins UC San Diego Chancellor's Startup of the Year Award
Vektor Medical is thrilled to announce that it has been awarded the prestigious Faculty Startup of the Year Award at the UC San Diego Chancellor's Innovation Awards!
A heartfelt thank you goes out to the UC San Diego Office of Innovation and Commercialization for their ongoing support of entrepreneurs and innovative ideas.
As this milestone is celebrated, Vektor Medical is motivated to continue its mission of revolutionizing arrhythmia care.
Vektor Medical Secures $16 Million Series A Funding
Vektor Medical today announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science. This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.
Funding will support the commercialization of vMap, which is transforming how EPs approach ablation procedures. To bolster this expansion, Vektor will increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation as well as continue efforts to secure reimbursement.
Data Demonstrating vMap’s Impact on Atrial Fibrillation Treatment Outcomes Unveiled at AF Symposium 2024
Vektor released findings at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by [vMap] in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.
Key Data Points:
- All patients in the study group (n=27) and controls (n=54) underwent standard-of-care pulmonary vein isolation (PVI).
- Following PVI, the study group (n=27) had ablation of 1.6 ± 0.7 additional AF driver sites identified by vMap’s artificial intelligence-based analysis.
- During ablation, 15 patients in the study group had driver site ablation during ongoing AF or focal AT resulting in atrial termination in 80% of such cases.
- 86.5% of patients in the vMap study group were free from AF and AT on or off antiarrhythmic medications at 1-year follow-up, compared to 48.0% of the control group.
Vektor Medical 2023 Year In Review
Dive into Vektor Medical's remarkable journey through 2023, marked by vMap enhancements, impactful clinical studies, and the establishment of a world-class Medical Advisory Board.
Explore the highlights that define a year filled with achievements, setting the stage for an exciting future.
New Studies Showcasing vMap’s Applications in the Analysis and Treatment of Ventricular Arrhythmias to be Presented at AHA ‘23.
The studies, conducted by Dr. Gordon Ho, promise to transform how we manage ventricular arrhythmias.
In the first study, "Improving Ablation Success with vMap in Unstable Ventricular Tachycardia," Dr. Ho addresses the challenge of treating unstable ventricular tachycardia (VT) with high recurrence rates. The research demonstrated vMap's ability to pinpoint VT locations, resulting in a remarkable 99% reduction in ICD shocks for patients undergoing vMap-guided VT ablation.
In the second study, "Enhancing Surgical Ablation with Pre-Operative vMap Analysis," Dr. Ho introduced a novel pre-operative workflow using vMap to localize ventricular arrhythmias in cardiac surgery patients. This approach led to a 100% decrease in VT/VF episodes and a 97.2% reduction in PVC burden during follow-up.
vMap Awarded a New Category III CPT Code
The American Medical Association (AMA) CPT Editorial Panel has approved a new Category III CPT code for the application of #vMap's novel noninvasive arrhythmia analysis.
“This is a significant and pivotal milestone for the company, and we are deeply honored to receive the AMA's confirmation that vMap provides unique value deserving of appropriate recognition.” Rob Krummen, CEO of Vektor Medical stated.
The AMA CPT Editorial Panel is set to publish the code describing vMap’s noninvasive arrhythmia analysis by January 1, 2024, for effective implementation on July 1, 2024.
Vektor Medical Expands Its Medical Advisory Board
Vektor Medical is thrilled to announce the expansion of its Medical Advisory Board, featuring distinguished electrophysiology leaders, including Dr. John Miller (IndianaUniversity Health), Dr. Jag Singh (Mass General Brigham), Dr. Ben D’Souza(UPenn Medicine), Dr. Ulrika Birgersdotter-Green (UC San Diego Health), Dr.David Haines (Beaumont Hospital), Dr. Gery Tomassoni (Baptist Health), and Dr.Greg Feld (UC San Diego Health).
The dilemma healthcare providers are facing right now is how to increase access to cardiovascular care, while health systems are stretched and resources are limited. Non-invasive, digital tools like vMap, powered by artificial intelligence algorithms, are not only enhancing physician’s ability to diagnose and treat cardiac arrhythmias with unprecedented accuracy and efficiency, but also spearheading healthcare transformation through digital innovation, enabling health providers deliver care to more patients,” said Dr. Jag Singh.
Vektor Medical Unveils Cutting-Edge, AI-based Arrhythmia Research at HRX 2023
Vektor is set to showcase two innovative research breakthroughs at HRX 2023, the Heart Rhythm Society’s digital health innovation conference.
The company's Chief Technology Officer, Chris Villongco, Ph.D., and Vice President of Technology, Christian Márton, Ph.D., were selected as AbstracX Innovators and will unveil groundbreaking research on CT Scar Imaging and Wall Thickness Analysis, illuminating the broad potential of non-invasive arrhythmia analysis and Vektor's vMap technology.
In The News: LSI Emerging MedTech Today Podcast
Vektor's CEO, Rob Krummen, and Chief Business Development Officer, Lana Caron, engage in a captivating conversation with Henry Peck on LSI's Emerging MedTech Today podcast. They delve into the remarkable progress we're achieving with vMap, driving positive advancements in arrhythmia care.
"We set out to create a product that enhances outcomes, safety, costs, and efficiencies. And we're excited that all of our early data is hitting on those points."
Vektor Medical Brings AI to Cardiac Arrhythmias
Vektor CEO Rob Krummen joined Matt Henriksson on the Bloomberg Intelligence: Vanguards of Health Care podcast for an in-depth interview on Vektor, how vMap utilizes a standard 12-lead ECG to analyze & map cardiac arrhythmias, and the future of utilizing the technology for cardiac ablations.
vMap Software Enhancements
Vektor Medical today announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap.
Designed to improve ablation outcomes and procedural efficiencies, the newly updated vMap software integrates additional automation and advanced visualization features.
The software upgrades are designed to improve the accuracy, visualization, and efficiency of arrhythmia analysis and interpretation.
Vektor Medical Releases Compelling Results for vMap Utility at HRS 2023
vMap’s use with ‘Unmappable’ Ventricular Tachycardia ablation and accurate proof-of-concept mapping using outpatient 12-lead ECG data to be presented at the Heart Rhythm Society’s Annual Conference in New Orleans.
In The News: Cardio Conversations
During an episode of the Cardio Conversations podcast, Medtech Insight's Reed Miller interviewed Vektor CEO Rob Krummen. Their discussion covered everything from the significance of ECG mapping and the potential benefits of unlocking the data contained within it.
New Study Demonstrates vMap Associated with Significantly Improved Outcomes in Atrial Fibrillation Treatment
Use of vMap during complex atrial fibrillation (AF) ablation was associated with significantly improved freedom from atrial arrhythmias compared with standard-of-care pulmonary vein isolation.
The study found that additional AF driver site ablation guided by vMap was associated with an 87.5% freedom from all atrial arrhythmias compared with the control arm’s 58.0% arrhythmia-free survival (p=0.043).
The results were presented at the Biomarkers and Personalized Medicine in Cardiovascular Disease Symposium on Saturday, March 25, in La Jolla, California.
New Data Showcasing vMap’s Utility to Map Complex Arrhythmias to be Presented at American College of Cardiology 2023
Case studies highlighting vMap’s effectiveness at localizing arrhythmia termination sites in complex cases to be presented alongside vMap time study.
The two complex clinical case studies, highlight the use of vMap to guide the successful cryoablation of PVCs near the intramural anomalous coronary artery and concomitant surgical ventricular tachycardia (VT) and ventricular fibrillation (VF) ablation during left ventricular assist device (LVAD) implantation. The new results add to the growing body of evidence that demonstrates vMap’s utility for the successful treatment of a wide range of arrhythmias, including surgical ablation.
New AF and Congenital Heart Disease Data on vMap Presented at APHRS
New data was presented that demonstrated vMap's potential utility in patients with adult congenital heart disease and refractory atrial fibrillation at the recent Annual Asia Pacific Heart Rhythm Society (APHRS) Scientific Session.
“These initial clinical results that show successful mapping with vMap in complex cases are promising," said Sutton Fox M.D., UC San Diego Health. "Although additional studies are needed, we are optimistic that future clinical results may reinforce vMap’s usability for a broader range of patients, which ultimately has the potential to improve patient outcomes for millions of people with adult congenital heart disease and refractory atrial fibrillation.”
New Data Demonstrates vMap Reduces Procedural Duration, Fluoroscopy Use, and Cost
In the presentation titled Forward-Solution Computational Arrhythmia Mapping is Associated with Decreased Procedural Time, Fluoroscopy Use, and Cost, Toomu presented findings from a retrospective, case-control study evaluating the hypothesis that non-invasive computational ECG mapping reduces overall procedure time, fluoroscopy use, and cost in the EP lab setting. The poster presentation won first place in the research category.
vMap exhibited a reduction in total procedure duration of 68 minutes (227±54 vs. 295±77 minutes, p<0.001), reduction in fluoroscopy time of 16.3 minutes (18.4±13.9 vs. 34.7±16.6 minutes, p<0.001), and EP lab costs ($2,267). Use of vMap was also associated with a reduced use of 64-electrode basket catheters in atrial fibrillation ablation cases (p=0.025)
Circulation: Arrhythmia and Electrophysiology Publishes vMap Clinical Data
Circulation has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy vMap®. The study shows 97.3% accuracy in identifying arrhythmia source locations in nine atrial and ventricular arrhythmias and pacing types across all four heart chambers.
The article titled, “Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study” was authored by researchers and cardiologists at the Department of Medicine at the University of California San Diego, Veterans Affairs San Diego Healthcare System, Mills Peninsula Medical Center, Medical University of South Carolina, Katherine Kacena Consulting, Technomics Research, the Department of Bioengineering at the University of California San Diego, and Vektor Medical, Inc.